The Challenges and Opportunities of the Implementation of Comprehensive Genomic Profiling in Everyday Clinical Practice with Non-Small Cell Lung Cancer: National Results from Croatia.
NSCLC
comprehensive genomic profiling
precision medicine
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
28 Jun 2023
28 Jun 2023
Historique:
received:
31
05
2023
revised:
26
06
2023
accepted:
27
06
2023
medline:
14
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
Non-small cell lung cancer (NSCLC) has become the best example of precision oncology's impact on outcomes in everyday clinical practice, significantly changing the expectations of all stakeholders, including medical professionals, society, and most importantly, patients. Consequently, the implementation of the precision oncology concept in medical systems, in order to achieve optimal and proven curative effects in NSCLC, is imperative. In this study, we investigated the development, challenges, and results associated with the implementation of precision oncology in NSCLC on a national level in Croatia. We conducted a multicenter, retrospective, cross-sectional analysis on the total population of Croatian patients with metastatic lung cancer, on whose tumors specimen comprehensive genomic profiling (CGP) testing was performed during 2020 and 2021. A total of 48 patients were included in the study. CGP revealed clinically relevant genomic alterations (CRGA) in 37 patients (79%), with a median of 2 (IQR 1-3) CRGA per patient. From the panel of recommended tests,
Identifiants
pubmed: 37444505
pii: cancers15133395
doi: 10.3390/cancers15133395
pmc: PMC10340418
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
PLoS One. 2020 Sep 25;15(9):e0237802
pubmed: 32976510
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Arch Dis Child Educ Pract Ed. 2013 Dec;98(6):236-8
pubmed: 23986538
Ann Oncol. 2023 Apr;34(4):339-357
pubmed: 36872130
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Lung Cancer. 2017 Jan;103:27-37
pubmed: 28024693
Lung Cancer. 2020 Oct;148:69-78
pubmed: 32823229
J Clin Oncol. 2018 Aug 20;36(24):2532-2537
pubmed: 29989854
Clin Lung Cancer. 2017 Nov;18(6):651-659
pubmed: 28479369
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
Oncologist. 2014 Oct;19(10):e5-11
pubmed: 25170012
Cancers (Basel). 2020 Jun 19;12(6):
pubmed: 32575424
Lung Cancer. 2022 May;167:41-48
pubmed: 35397297
Curr Oncol. 2023 Feb 15;30(2):2348-2365
pubmed: 36826141
Oncologist. 2018 Jun;23(6):740-745
pubmed: 29438093
Nat Biotechnol. 2013 Nov;31(11):1023-31
pubmed: 24142049
JCO Precis Oncol. 2023 Jan;7:e2200294
pubmed: 36634300
Respir Med Case Rep. 2019 Jul 10;28:100901
pubmed: 31367517
Ann Oncol. 2019 Apr 1;30(4):597-603
pubmed: 30891595
Pathol Oncol Res. 2021 Mar 11;27:592997
pubmed: 34257540
Oncologist. 2016 Jun;21(6):684-91
pubmed: 27151654
N Engl J Med. 2014 Nov 20;371(21):1963-71
pubmed: 25264305
Am Soc Clin Oncol Educ Book. 2019 Jan;39:531-542
pubmed: 31099633
Front Immunol. 2020 Mar 06;11:369
pubmed: 32210966
Curr Oncol. 2022 Jul 08;29(7):4811-4826
pubmed: 35877242
Nat Rev Dis Primers. 2015 May 21;1:15009
pubmed: 27188576
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Oncologist. 2016 Jun;21(6):762-70
pubmed: 27245569
N Engl J Med. 2022 Jan 20;386(3):241-251
pubmed: 34534430
Am J Clin Pathol. 2012 Sep;138(3):332-46
pubmed: 22912349
J Clin Oncol. 2022 Feb 20;40(6):611-625
pubmed: 34985916
Ann Oncol. 2019 Feb 1;30(2):290-296
pubmed: 30535340
Nat Rev Clin Oncol. 2018 Dec;15(12):731-747
pubmed: 30333516
Ann Oncol. 2018 Aug 1;29(8):1869-1876
pubmed: 29912274
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
Lung Cancer. 2018 Oct;124:53-64
pubmed: 30268480
BMC Med. 2021 Oct 1;19(1):223
pubmed: 34592968